REPROCELL announced today we have launched a cutting-edge genome editing service utilizing next-generation CRISPR/Cas9 technology, called SNIPER. This service is offered in collaboration with GenAhead Bio Inc. (Kanagawa, Japan; hereinafter referred to as “GenAhead”). GenAhead is a venture company established by a team of experts in genetic modification technology. Since April 2018, REPROCELL has had a strategic investment in GenAhead.
By combining the cutting-edge genome editing technology CRISPR/Cas 9 with their own SNIPER technology, GenAhead can offer highly efficient and accurate genome editing technology service. REPROCELL has been offering the most advanced iPS cell outsourcing service using the RNA reprogramming method, providing iPS cells derived from cells collected from patients. By combining our most advanced iPS cell production technology with GenAhead’s cutting-edge genome editing technology, we can provide high precision genome editing iPS cells that had been difficult to provide before.
High precision genome editing service for iPS cells has developed as a key drug discovery tool for pharmaceutical companies to accelerate the development or new therapeutics. REPROCELL and GenAhead are now a leading provider of genomic editing iPS cells with the high accuracy.
The CRISPR/Cas 9 system is a cutting-edge genome editing technology capable of precisely altering arbitrary regions in the genome. Research has been expanding globally in the use of CRISPR/Cas 9 technology for not only basic research, but also to study the reproduction of microorganisms, improve breeds of plants and animals, prepare disease model cells for drug discovery applications, and develop new cancer treatments.
For more information, please contact email@example.com.
Strategy and Marketing Planner, REPROCELL
Sign up to receive information from REPROCELL about our products, services, applications, promotions, and news (includes a weekly blog update email).